India approves Gilead’s remdesivir to treat severe COVID-19 cases

According to a recent report, the Indian government has approved the use of Gilead Sciences Inc’s antiviral drug remdesivir for emergency use in treating COVID-19. Remdesivir, which is administered intravenously in hospitals, is the first drug to show improvement in COVID-19 patients in formal clinical trials and is at the forefront of the battle against COVID-19, which has no approved treatment or vaccine.  The said drug is only allowed to be used as a treatment based on a 5 dose trial according to the drug controller general of India. The DCGI has granted regulatory approval of remdesivir for treatment of suspected or laboratory-confirmed COVID-19 in adults and children hospitalized with severe disease The drug was granted emergency use authorization by the U.S. Food and Drug Administration last month and has received approval by Japanese health regulators. While there is a limited global supply of remdesivir, the company anticipates a new supply of the drug to start to become available in July, said the drugmaker. Governments are racing to bolster supplies of remdesivir, with European and South Korean authorities vying for the potential COVID-19 treatment.

To know more about origin, virology of COVID-19, Click here

To know more about emerging themes in COVID-19, Click here

To know more about how WhiteCoats can help you in your professional advancement, visit

Want to set up an online consultation for your practice, Click here